Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2198 | Low fat "standard care" control breakfast Wiki | 1.00 |
| drug2575 | No intervention Wiki | 0.21 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The prevalence of type 2 diabetes (T2D) is increasing worldwide, with ~380 M currently suffering from this chronic, debilitating disease. T2D is characterized by high blood glucose levels in the mornings and after meals. The largest hyperglycemic spike often occurs after breakfast. Targeting this meal may be a simple, feasible strategy to improve glycemic control and reduce risk for diabetes complications. It is hypothesized that consuming a low carbohydrate high fat (LCHF) breakfast for 3 months, when compared to a standard low-fat breakfast will improve blood glucose control, increase satiety and improve body composition in people with T2D. This information will test whether the simple dietary strategy of limiting carbohydrates at breakfast could help in managing T2D.
Description: Hemoglobin A1c measured at baseline and after 12 weeks of following the low-carbohydrate breakfast or low-fat breakfast
Measure: Change from Baseline Hemoglobin A1c at 12 weeks Time: Baseline to 12 weeks of dietDescription: Fasting blood glucose measured at baseline and after 12 weeks of following the low-carbohydrate breakfast or low-fat breakfast
Measure: Change from Baseline Fasting blood glucose at 12 weeks Time: Baseline to 12 weeks of dietDescription: Fasting blood insulin measured at baseline and after 12 weeks of following the low-carbohydrate breakfast or low-fat breakfast
Measure: Change from Baseline Fasting blood insulin at 12 weeks Time: Baseline to 12 weeks of dietDescription: Triglycerides, total, HDL, and LDL cholesterol at baseline and after 12 weeks of following the low-carbohydrate breakfast or low-fat breakfast
Measure: Change from Baseline Blood Lipids at 12 weeks Time: Baseline to 12 weeks of dietDescription: Blood inflammation marker (hsCRP) at baseline and after 12 weeks of following the low-carbohydrate breakfast or low-fat breakfast
Measure: Change from Baseline Inflammation marker High sensitive Reactive Protein (hsCRP) at 12 weeks Time: Baseline to 12 weeks of dietDescription: Levels of hunger and satiety measured by a 0 to 100 millimeter visual analog scale [ranges across a continuum from none (0) to an extreme amount (100) of Hunger, Satiety, Fullness, Appetite]
Measure: Hunger/satiety levels Time: 12 weeksDescription: Total calorie intake assessed by 24 hour food record
Measure: Change from Baseline Caloric intake at 12 weeks Time: Baseline to 12 weeks of dietDescription: Body weight measured in kilograms at baseline and after 12 weeks of following the low-carbohydrate breakfast or low-fat breakfast
Measure: Change from Baseline Body weight at 12 weeks Time: Baseline to 12 weeks of dietDescription: Body mass Index measured in weight in kilograms divided by the square of height in meters at baseline and after 12 weeks of following the low-carbohydrate breakfast or low-fat breakfast
Measure: Change from Baseline Body Mass Index at 12 weeks Time: Baseline to 12 weeks of dietAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports